In T1DM, insulin-producing pancreatic β cells are recognized and destroyed by the self-reactive immune responses, resulting in insulin deficiency, and therefore, T1DM patients require lifelong therapy with exogenous insulin (Katsarou et al., 2017). This evidence concerns the gene INS and type 1 diabetes mellitus.